Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Dec 31, 2022 11:38am
108 Views
Post# 35198387

RE:RE:RE:RE:RE:Midatech at $1.0475

RE:RE:RE:RE:RE:Midatech at $1.0475
Let's get it straight. Mei Mei Tian, Saltarelli and Rathjen, because they will be joining Biodexa and receiving benefits that no shareholder can get, have no credibility when it comes to describing to shareholders how great this is.
 
There are many maxims in the world of marketing and promotion. One of them is to never promote the opinions of those who came from the ranks of your target audience and gained privilege and benefits that your target audience cannot possibly achieve and will likely resent. 
 
This post by prophetoffactz is extraordinarily insensitive, which proves what we have always known about him. He pumps his interests with no consideration of values.
 
For goodness sakes, of course Tian, Saltarelli and Rathjen think this is swell. But if there ever was a time for them to just shut up and stay out of sight, this is it. They failed. They failed to build Bioasis. They actively played down the Bioasis assets during the past 18 months. And they have been rewarded for that failure.
 
Let Stephen Stamp be the face of this. Like all CEOs, he's the promoter-in-charge and has the responsibility to achieve what he's promoting. The others escaped Bioasis to their great advantage. The shareholders could not.

jd
<< Previous
Bullboard Posts
Next >>